Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165399 · ClinicalTrials.gov registry record · Phase 2
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00165399 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 62 participants.
The verdict
NCT00165399, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer. This study will attempt to: * stop or slow the growth of disease * gain information about prostate cancer * evaluate the effectiveness and side effects of the study drug
Interventions
- DRUG Docetaxel
- DRUG Zoladex
- DRUG Estramustine
- DRUG Casodex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00165399
The ClinicalTrials.gov registry entry for NCT00165399 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT00165399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00165399 about?
NCT00165399 is a clinical study titled "Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment". The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer. This study will attempt to: * stop or slow the growth of disease * gain information about prostate cancer * evaluate ...
What is the current status of trial NCT00165399?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2004-03. Estimated completion is 2005-12-31.
What interventions are being tested in trial NCT00165399?
The interventions under investigation include: Docetaxel (DRUG), Zoladex (DRUG), Estramustine (DRUG), Casodex (DRUG).
Who is sponsoring clinical trial NCT00165399?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.